AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

EMA

7 April 2021 - EMA confirms overall benefit-risk remains positive.

EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).

In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Europe , Regulation , Vaccine , Safety , COVID-19